/ /

  • linkedin
  • Increase Font
  • Sharebar

    Latanoprostene bunod shows promise in patients with open-angle glaucoma, ocular hypertension

    New compound showing better efficacy than timolol over a 24-hour period

     

    Take-home

    Findings from the CONSTELLATION study show that once-daily latanoprostene bunod lowered IOP more than twice-daily timolol in patients with open-angle glaucoma or ocular hypertension.

     

     

    La Jolla, CA—Once-daily latanoprostene bunod lowered IOP more than twice-daily timolol in an 8-week randomized crossover study of patients with open-angle glaucoma or ocular hypertension, according to results from the CONSTELLATION study.

    Lead author for the study, John H. Liu, PhD, of the Department of Ophthalmology and Hamilton Glaucoma Center, University of California–San Diego, La Jolla, CA, said the randomized, single-center, open-label, 2-period, 8-week study included a crossover at 4 weeks between latanoprostene bunod 0.024% once-daily with timolol maleate 0.5% twice-daily.

    “A comparison against timolol is an industry standard,” he said. “I hope that this new compound will be compared against other prostaglandin analogues in the future.”

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results